CCA
LIMN

Cygnus Capital Advisors’s Liminatus Pharma LIMN Stock Holding History

Cygnus Capital Advisors’s Portfolio LIMN Stock Details LIMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36K Sell
6,587
-413
-6% -$3.57K 0.02% 62
2026
Q1 		$60K Buy
+7,000
New +$187K 0.04% 67

Other funds holding LIMN

XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Personalized Indexing Management
Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return

Cygnus Capital Advisors's LIMN Position: Q2 2026 in Review

Cygnus Capital Advisors reduced its Liminatus Pharma (LIMN) stake by 5.9% in Q2 2026, selling an estimated $3.57K and leaving 6,587 shares worth $36K. The position accounts for 0.02% of the portfolio, ranked #62.

Cygnus Capital Advisors first reported a position in LIMN in Q1 2026 and has held it in 2 quarters since. The position peaked at $60K in Q1 2026. 14 funds tracked by Wall St. Rank hold LIMN as of Q2 2026.

  • Cygnus Capital Advisors held 6,587 shares of Liminatus Pharma worth $36K as of Q2 2026.
  • Cygnus Capital Advisors sold 413 Liminatus Pharma shares in Q2 2026, an estimated $3.57K.
  • Liminatus Pharma made up 0.02% of Cygnus Capital Advisors's portfolio in Q2 2026, its #62 holding.
  • Cygnus Capital Advisors first reported a position in Liminatus Pharma in Q1 2026 and has held it in 2 quarters since.
  • Cygnus Capital Advisors's Liminatus Pharma position peaked at $60K in Q1 2026.
  • 14 funds tracked by Wall St. Rank held Liminatus Pharma as of Q2 2026.

Based on Cygnus Capital Advisors's 13F filing for Q2 2026, filed 3 Sep 2026.